Byetta & Januvia

Byetta & Januvia Pancreatic Cancer

The Type 2 diabetes drugs Byetta® (exenatide) or Januvia® (sitagliptin) are prescribed to help improve blood sugar levels along with lifestyle changes, such as diet and exercise. While both of these drugs work differently, they pose the same risk to patients—serious pancreatic problems, including pancreatic cancer.

Our law firm represents patients who were prescribed Byetta or Januvia and developed pancreatic cancer. If you or a family member were diagnosed with pancreatic cancer after taking either of these Type 2 diabetes drugs, we’re ready to help protect your rights to compensation. Contact our legal team 24/7 for a free initial consultation—call or fill out our online form to take action now.

Byetta® and Januvia® Linked to Risk of Pancreatic Cancer

A drug safety communication from the U.S. Food and Drug Administration (FDA) reported that officials from the agency intend to study the potential link between pancreatic cancer and Type 2 diabetes drugs like Byetta and Januvia.

In addition to citing that both of these drugs may double the risk of acute pancreatitis, the FDA has also warned that Byetta and Januvia may increase the risk of potentially fatal pancreatitis. But despite warnings of pancreatitis on drug packaging for Byetta and Januvia, the labels fail to warn patients of a potential pancreatic cancer risk.

Byetta® and Januvia® Pancreatic Cancer Lawsuits

If you or a loved one were diagnosed with pancreatic cancer after taking Byetta or Januvia, contact our drug injury lawyers for a free case review now. We’re standing by to put our knowledge and experience to work on your injury claim—call our legal team or complete our online form anytime to get help now.

Byetta® is a registered trademark of Amylin Pharmaceuticals, Inc. Januvia® is a registered trademark of Merck & Co., Inc.

This law firm is not associated with, sponsored by, or affiliated with the U.S. Food and Drug Administration; Amylin Pharmaceuticals, Inc.; or Merck & Co., Inc.